The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
CONTEXT The Women 's Health Initiative ( WHI ) trial of estrogen plus progestin was stopped early because of adverse effects , including an increased risk of stroke in the  estrogen plus progestin group . OBJECTIVE To assess the effect of estrogen plus progestin on ischemic and hemorrhagic stroke and in subgroups , and to determine whether the effect of estrogen plus progestin was modified by baseline levels of blood biomarkers . DESIGN Multicenter double-blind , placebo-controlled , r and omized clinical trial involving 16 608 women aged 50 through 79 years with an average follow-up of 5.6 years . Baseline levels of blood-based markers of inflammation , thrombosis , and lipid levels were measured in the first 140 central ly confirmed stroke cases and 513 controls . INTERVENTIONS Participants received 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate ( n = 8506 ) or placebo ( n = 8102 ) . MAIN OUTCOME MEASURES Overall strokes and stroke subtype and severity were central ly adjudicated by stroke neurologists . RESULTS One hundred fifty-one patients ( 1.8 % ) in the estrogen plus progestin and 107 ( 1.3 % ) in the placebo groups had strokes . Overall 79.8 % of strokes were ischemic . For combined ischemic and hemorrhagic strokes , the intention-to-treat hazard ratio ( HR ) for estrogen plus progestin vs placebo was 1.31 ( 95 % confidence interval [ CI ] , 1.02 - 1.68 ) ; with adjustment for adherence , the HR was 1.50 ( 95 % CI , 1.08 - 2.08 ) . The HR for ischemic stroke was 1.44 ( 95 % CI , 1.09 - 1.90 ) and for hemorrhagic stroke , 0.82 ( 95 % CI , 0.43 - 1.56 ) . Point estimates of the HRs indicate that excess risk of all stroke was apparent in all age groups , in all categories of baseline stroke risk , and in women with and without hypertension , prior history of cardiovascular disease , use of hormones , statins , or aspirin . Other risk factors for stroke , including smoking , blood pressure , diabetes , lower use of vitamin C supplements , blood-based biomarkers of inflammation , higher white blood cell count , and higher hematocrit levels did not modify the effect of estrogen plus progestin on stroke risk . CONCLUSIONS Estrogen plus progestin increases the risk of ischemic stroke in generally healthy postmenopausal women .  Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined
The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .